GlassScriptPhysician profile
Emily Christine Mcdevitt
NPI 1881892446
$2,880.00
in general payments reported to CMS, 2019-2025
25 companies · $541 in 2025
The $541 reported for 2025 was more than what 75% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $266 · 2022: $594 · 2023: $835 · 2024: $644 · 2025: $541.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,020.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,019.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $508.83 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $442.62 | 2022-2025 | |
| Lilly USA, LLC | $324.74 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Astrazeneca Pharmaceuticals LP | $205.12 | 2022-2025 | Airsupra, Farxiga |
| Abbvie INC. | $173.43 | 2022-2025 | |
| Glaxosmithkline, LLC. | $146.74 | 2021-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Amgen INC. | $133.40 | 2021-2024 | Evenity, Prolia |
| Abbott Laboratories | $121.19 | 2023 | Mitraclip |
| Acclarent, INC | $117.06 | 2023 | Acclarent Aera |
| Boston Scientific Corporation | $112.99 | 2022-2025 | Watchman Flx, Watchman |
| Dexcom, INC. | $98.16 | 2023-2024 | Dexcom G6 Transmitter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $89.19 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $67.36 | 2022-2024 | Xifaxan, Trulance |
| Bayer Healthcare Pharmaceuticals INC. | $66.95 | 2022-2025 | |
| Eisai INC. | $47.97 | 2021 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $43.91 | 2021-2023 | Lagevrio, Belsomra |
| Biohaven Pharmaceutical Holding Company LTD. | $40.63 | 2022 | |
| Sumitomo Pharma America, INC. | $27.36 | 2023-2025 | Gemtesa |
| Takeda Pharmaceuticals U.S.A., INC. | $20.94 | 2022 | |
| Astellas Pharma US INC | $20.80 | 2025 | Veozah |
| Janssen Pharmaceuticals, INC | $17.12 | 2023 | Xarelto |
| Exact Sciences Corporation | $14.44 | 2023 | Cologuard Collection Kit |
| Kowa Pharmaceuticals America, INC. | $13.23 | 2021 | |
| Sanofi Pasteur INC. | $13.05 | 2021 | |
| Genentech USA, INC. | $12.77 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emily Mcdevitt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.